Reuters
U.S. looking to broaden access to COVID-19 antiviral pills – WSJ
The administration is reviewing whether Paxlovid, the antiviral from Pfizer Inc, can be available on the commercial market in retail pharmacies if it gets regulatory clearance, the Journal reported. Molnupiravir, an oral pill from Merck & Co Inc and Ridgeback Biotherapeutics LP that is also under regulatory review, may be included in the government’s plan to make it commercially available, the journal reported, citing the person. The United States has agreed to buy 10 million courses of Pfizer’s drug and has so far secured 3.1 million courses of Merck’s pill.
